Prelude Capital Management, LLC Adma Biologics, Inc. Transaction History

Prelude Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$1.8 - $2.56 $58,154 - $82,708	-32,308 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$2.04 - $3.74 $65,908 - $120,831	32,308 New	32,308 $77,000
Q4 2018 Feb 14, 2019	SELL	$2.17 - $6.12 $102,858 - $290,088	-47,400 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$4.39 - $6.85 $50,392 - $78,631	-11,479 Reduced 19.5%	47,400 $294,000
Q2 2018 Aug 14, 2018	BUY	$4.39 - $5.44 $6,931 - $8,589	1,579 Added 2.76%	58,879 $266,000
Q1 2018 May 15, 2018	BUY	$3.21 - $5.21 $47,906 - $77,754	14,924 Added 35.22%	57,300 $264,000
Q4 2017 Feb 14, 2018	BUY	$2.06 - $3.24 $6,954 - $10,938	3,376 Added 8.66%	42,376 $136,000
Q3 2017 Nov 14, 2017	BUY	$2.76 - $3.71 $107,639 - $144,690	39,000	39,000 $120,000

339

182M

1.72M

846K

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.05B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.